RxDoctor Payments Data

Ashley Walker

Psychiatric/Mental Health · Memphis, TNNPI 1245014075

Payments from drug & device makers

$1,452in general payments, 2019–2025

Across 73 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$341
  • Johnson & Johnson$287
  • Alkermes, Inc.$209
  • Otsuka America Pharmaceutical, Inc.$195
  • Vanda Pharmaceuticals Inc.$176
  • Lundbeck LLC$85
  • plus $160 from 3 others

What the payments were for

  • Food & beverage$1,37495%
  • Education$785%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,452 in reported general payments places this provider in the 65th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,194
Medicare patients
22
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate14$108,582
Invega SustennaPaliperidone Palmitate34$82,836
Abilify MaintenaAripiprazole11$30,400
Lurasidone Hcl46$7,897
Aripiprazole90$5,621
Oxcarbazepine34$2,117
Ziprasidone Hcl26$1,229
Haloperidol Decanoate37$1,222
Hydroxyzine Pamoate39$1,214
Quetiapine Fumarate68$1,182
Fluphenazine Decanoate47$1,035
Hydroxyzine Hcl50$940
Benztropine Mesylate79$870
Buspirone Hcl49$747
Trazodone Hcl85$595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$341$108,58214 claims
Johnson & JohnsonInvega Sustenna$287$82,83634 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$195$30,40011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →